D3 Bio

D3 Bio is a clinical-stage biotechnology company focused on discovering, developing, and registering new oncology and immunology medicines. They leverage clinical insight and biomarker strategies to create novel therapies for patients. Their lead asset, D3S-001, is a next-generation KRAS G12C inhibitor currently in Phase II development.

Buy Funded Startups lists

Funding Round: Series A+

Funding Amount: $62M

Date: 08-Apr-2024

Investors: Medicxi, Matrix Partners China, WuXi AppTec's Corporate Venture Fund

Markets: Biotechnology, Oncology, Immunology, Life Science, Pharmaceutical

HQ: Wuxi, Jiangsu, China

Founded: 2018

Website: https://www.d3bio.com/

LinkedIn: https://www.linkedin.com/company/d3bio

Twitter:

Instagram: